MTOR and cancer: We propose a model for the action of these combination therapies in breast and colon cancer in which the antineoplastic drugs inhibit autophagy, resulting in cell death, with the simultaneous targeting of PPT1 by the repurposed drugs, leading to mTOR inactivation and consequently decreasing the cellular protein synthesis and cancer cell growth.